logo

Delmar Pharmaceuticals, Inc. (DMPI)



Trade DMPI now with
  Date
  Headline
9/10/2019 8:07:27 AM DelMar Pharma FY Net Loss Of About $8.0 Mln Or $3.16/shr Vs. Net Loss Of $11.1 Mln Or $5.42/shr Prior Year
9/9/2019 8:11:43 AM DelMar Reports Full Compliance With Nasdaq Listing Criteria
9/4/2019 8:32:20 AM DelMar Pharma Relocates Headquarters To San Diego, California
8/27/2019 8:35:33 AM DelMar Expects Cash Runway Will Provide Capital For Full Enrollment In All Three Patient Groups In Two Phase 2 Trials
8/14/2019 9:12:33 AM DelMar Pharma Announces Pricing Of $6.8 Mln Underwritten Public Offering
8/13/2019 9:03:44 AM DelMar Reports Updated Results On Twenty Patients From The Phase 2 Clinical Trial Of VAL-083
7/24/2019 9:00:51 AM DelMar Enrolls First Patient In Adjuvant Setting Arm Of Phase 2 Study Of VAL-083 For Treatment Of MGMT
6/27/2019 5:32:44 AM Delmar Pharmaceuticals Announces Termination Of Rights Offering
6/11/2019 5:33:31 AM Delmar Adjusts Certain Pricing Information And Key Dates For Previously Announced Rights Offering
6/3/2019 8:52:18 AM DelMar Updates On VAL-083 From Ongoing First- And Second-Line Trials In Patients With MGMT-unmethylated Glioblastoma
6/3/2019 8:50:57 AM DelMar Plans $3.6 Mln Registered Direct Offering
5/20/2019 5:32:47 AM DelMar Appoints Three Additional World-class Neuro-oncologists To Its Scientific Advisory Board
5/15/2019 5:36:23 AM DelMar Pharma Q3 Net Loss Narrows To $1.66 Mln From $2.93 Mln Last Year
  
 
>